慢性移植物抗宿主病治疗反应的临床预测因素:PQRST试验结果
该前瞻性观察队列研究纳入接受一线至三线系统治疗的慢性GVHD患者,最佳缓解率为60%-70%,6个月降至40%;6个月无失败生存率为66%,18个月降至41%,且不因药物或治疗线数而异。未发现明确的FFS或生存临床预测因素,仅患者报告的疲劳与NIH缓解相关。
要点
- 慢性GVHD一线至三线系统治疗最佳缓解率60%-70%,6个月降至40%。
- 6个月无失败生存率66%,18个月降至41%,不因药物或治疗线数而异。
- 仅患者报告疲劳与NIH缓解相关,未发现其他临床缓解预测因素。
核心结论
- 当代慢性GVHD一线至三线治疗缓解率高但不持久,未发现明确的FFS或生存临床预测因素。
研究设计与样本
- 前瞻性观察队列研究,纳入开始一线、二线或三线指定药物系统治疗的慢性GVHD患者。
主要发现
- 最佳缓解率为60%-70%,6个月降至40%。
- 6个月无失败生存率为66%,18个月降至41%,不因药物或治疗线数而异。
- 患者报告疲劳与NIH缓解相关,未发现其他临床缓解预测因素。
- 6个月缓解者与1年时更高的FFS相关。
- 治疗缓解时多于一个器官改善,进展时通常一个器官受累。
临床怎么用
- 临床应预期一线至三线系统治疗缓解率高但6个月后下降,需关注6个月缓解状态以评估1年FFS。
局限性
- 未发现明确的临床预测因素,需进一步研究识别临床和生物学表型及治疗反应预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite significant progress in chronic GVHD therapies, challenges remain in understanding pleomorphic phenotypes and varying responses to treatment. The aim of this study was to identify predictors of treatment response. We conducted a prospective, observational cohort study of patients beginning first-, second-, or third-line systemic therapy for chronic GVHD with defined agents. We describe best and 6-month response rates, failure-free survival (FFS), and clinical predictors of response. Best response rates were 60%-70% to index therapies, which subsequently declined to 40% at 6 months. Similarly, failure-free survival at 6 months was 66%, but dropped to 41% at 18 months and did not vary based on agent or line of therapy. No clear clinical predictors of FFS or survival were identified. Patient-reported fatigue was associated with NIH response, but we did not find any other clinical predictors of response. Six-month responders were associated with higher FFS at 1 year. When patients were responding to therapy, more than one organ improved. Conversely, one organ usually accounted for patients progressing. In the contemporary era, we demonstrate high but not durable responses across all agents and the first three lines of therapy. There remain large variations in practice, and no specific patterns of agents used, organ responsiveness, or overall responsiveness were identified. Additional study is needed to identify clinical and biologic phenotypes and define predictors of treatment response. Trial Registration: clinicaltrials.gov identifier: NCT04431479.
引用
- Hamilton BK, Onstad L, Carpenter PA, et al. Clinical Predictors of Response in Chronic Graft-Versus-Host Disease: Results From the "Predicting the Quality of Response to Specific Treatments (PQRST)" Trial. Am J Hematol. 2026. PMID: 42385358. doi:10.1002/ajh.70427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。